Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the three months ended September 30, 2026.
Total revenue was $2.2 million, compared to $2.4 million for the same period in 2025, representing a decrease of $140,000, or 5.9%. As expected, sales declined compared with the prior-year period, primarily reflecting lower dental product sales.
Gross profit for the three months ended September 30, 2026 and 2025 was $1.6 million. Gross margin was 72.3% for the three months ended September 30, 2026 compared with 69.5% for the same period in 2025. The increase in gross margin was primarily due to lower product costs relative to sales during the current-year period.
Operating expenses decreased by $424,000, or 15.3%, to $2.4 million for the three months ended September 30, 2026, compared with $2.8 million for the three months ended September 30, 2025. The decrease was primarily attributable to lower salaries and compensation, stock-based compensation, professional fees and contract-related expenses, partially offset by increased marketing, regulatory, warehousing and travel expenses.
MLSS shares poked ahead one cent, or 4.3%, to 30 cents.
Related Stories
